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Abstract
Background: MicroRNAs (miRNAs) have been shown to play a critical role in the development and progression of
nasopharyngeal carcinoma (NPC). Although accumulating studies have been performed on the molecular mechanisms
of NPC, the miRNA regulatory networks in cancer progression remain largely unknown. Laser capture microdissection
(LCM) and deep sequencing are powerful tools that can help us to detect the integrated view of miRNA-target
network.
Methods: Illumina Hiseq2000 deep sequencing was used to screen differentially expressed miRNAs in laser-
microdessected biopsies between 12 NPC and 8 chronic nasopharyngitis patients. The result was validated by
real-time PCR on 201 NPC and 25 chronic nasopharyngitis patients. The potential candidate target genes of the
miRNAs were predicted using published target prediction softwares (RNAhybrid, TargetScan, Miranda, PITA), and
the overlay part was analyzed in Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)
biological process. The miRNA regulatory network analysis was performed using the Ingenuity Pathway Analysis
(IPA) software.
Results: Eight differentially expressed miRNAs were identified between NPC and chronic nasopharyngitis patients
by deep sequencing. Further qRT-PCR assays confirmed 3 down-regulated miRNAs (miR-34c-5p, miR-375 and
miR-449c-5p), 4 up-regulated miRNAs (miR-205-5p, miR-92a-3p, miR-193b-3p and miR-27a-5p). Additionally, the
low level of miR-34c-5p (miR-34c) was significantly correlated with advanced TNM stage. GO and KEGG enrichment
analyses showed that 914 target genes were involved in cell cycle, cytokine secretion and tumor immunology, and so
on. IPA revealed that cancer was the top disease associated with those dysregulated miRNAs, and the genes regulated
by miR-34c were in the center of miRNA-mRNA regulatory network, including TP53, CCND1, CDK6, MET and BCL2, and
the PI3K/AKT/ mTOR signaling was regarded as a significant function pathway in this network.
Conclusion: Our study presents the current knowledge of miRNA regulatory network in NPC with combination of
bioinformatics analysis and literature research. The hypothesis of miR-34c regulatory pathway may be beneficial in
guiding further studies on the molecular mechanism of NPC tumorigenesis.
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Background
Nasopharyngeal carcinoma (NPC) is a highly invasive and
metastatic cancer that is widely prevalent in southern China
[1, 2]. During tumorigenesis and progression, multiple gen-
etic and epigenetic abnormalities synergistically disrupt
normal cell function, especially playing an important role in
NPC pathogenesis [3, 4]. In recent decades, microRNAs
(miRNAs) have been increasingly recognized as important
genetic regulators in the mammalian system [5]. Dysregula-
tion of miRNA expression in NPC can regulate tumor cell
growth, differentiation and apoptosis.
MiRNAs are endogenous, small (18–25 nt), non-protein-
coding RNA molecules which modulate many physiological
and pathological processes through down-regulating target
genes [6]. Previous studies mostly focused on single
miRNA, such as miR-138, a potential tumor suppressor
by targeting CCND1 [7]. But microRNA expression
profiles have been demonstrated to be unique for a better
understanding of different stages of tumor progression and
metastasis. Hence, it is necessary to use high-tech tools to
get a comprehensive miRNA analysis of NPC etiology.
Thus far, several high-throughput techniques have been
applied to identify deregulated miRNAs in NPC. Most
studies to date have applied microarray technique on
nasopharyngeal carcinoma and non-cancer nasopharyngi-
tis tissues, and some of them could identify the miRNAs
as a prognostic factor or recurrent marker from the dis-
tinctive miRNA expression profile [8–10]. But the results
failed to show good interplatform concordance. Both
Sengupta et al. and Luo et al. recruited microarray on
laser-microdissected tissues which including NPC and
normal surrounding epithelial cells, only three miRNAs
(miR-34c-5p, miR-29c and miR-34b-5p) were shared in
the list of abnormal expressions by comparing Sengupta’s
data and Luo’s data [11, 12]. The inconsistency may be ex-
plained by heterogeneity of samples and use of different
expression measuring platforms. To get the better data re-
producibility, we need some more robust tools to reduce
the disturbance of heterogeneity.
The advent of the deep sequencing provides a rapid
and high throughput tool that can be used to explore the
large miRNA pool, and possesses obvious advantages for
the identification of miRNA sequence variations and the
discovery of novel miRNAs [13]. Plieskatt et al. compared
miRNA expression in FFPE ( formalin fixed paraffin- em-
bedded tissue) from NPC cases and controls using both
microarray and RNA-Seq technologies, showed that
RNA-Seq could additionally indicate unknown miRNAs as-
sociated with NPC [14]. Deep sequencing technology was
considered as a more powerful and accurate tool in ex-
pression profile study, which would allow us to generate a
comprehensive insight into the networks constructed by
many more deregulated miRNAs not described in previous
studies, just like the study of Chang et al., which delivered a
clear picture of the global miRNA regulatory characteristics
in triple-negative breast cancer by deep sequencing [15].
To better characterise the specific signature of NPC
cells, we expand our observations by applying laser capture
microdissection (LCM) on NPC and chronic nasopharyngi-
tis samples to compare the miRNA signatures between
them. LCM can separate the truly transformed cancerous
cells from those other cell types commonly present in a
tumor tissue, such as immune cells, connective tissue and
new vasculature [16–18]. Wang et al. demonstrated the
feasibility and potential power of discovering miRNA
biomarkers in colorectal tumor tissue using the combin-
ation of LCM with miRNA microarrays [19], and with the
combination of LCM and microarray, Sengupta et al. iden-
tified miR-29c was important in regulating genes involved
in metastasis of NPC [11].
Herein, we aim to examine the miRNA expression
profile in clinical tissue samples of NPC patients, and
get better understanding of the miRNA regulatory net-
work. After bioinformatics analysis and literature review,
we identify miR-34c as an important partner in NPC
tumorigenesis, and propose that miR-34c-target genes
network (including CCND1, TP53, BCL2, CDK6, MET)
should be critical in mediating NPC cellular proliferation,
migration and invasion.
Methods
Patient samples and laser capture microdissection
A total of 213 NPC patients and 33 chronic nasopharyngitis
patients were recruited prospectively from Nanfang
Hospital (Southern Medical University, Guangzhou, China).
None of the patients had received anticancer treatments
before undergoing biopsy. Fresh tissues were snap frozen
in liquid nitrogen and stored at −160 °C. All samples
were pathologically confirmed. The patients were informed
about the sample collection and had signed informed con-
sent forms. TNM classification was according to the defini-
tions of the seventh edition of the UICC-American Joint
Committee on Cancer staging criteria. 12 NPC biopsy spec-
imens and 8 non-cancer nasopharyngitis biopsy samples
were chose for laser capture microdissection (LCM). The
controls were carefully selected to match the gender and
age distribution of NPC patients. Because the sample of
stage I failed to pass the quality control, we chose 2
cases of stage II, and 5 cases of each stage III IV
(Table 1). Specimens were first frozen-sectioned by using a
LEICA CM 1900 cryomicrotome. After hematoxylin and
eosin (H&E) staining, LCM was performed on a MMI
Cellcut Microdissection Instrument (Molecular Ma-
chines & Industries, Swiss). Phase contrast images were
acquired using OlympusIX71 microscope. The research
protocols were approved by the Ethics Committee of
Nanfang Hospital and registered in Clinical.trials.gov
(ID: NCT01171235).
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Small RNA deep sequencing
Total RNA, containing miRNA, was extracted using Tri-
zol Reagent (Invitrogen, CA) from laser-microdessected
samples, and passed the RNA quality control for sequen-
cing. The quality and integrity of total RNA was assessed
with Agilent 2100 Bioanalyzer (Agilent Technologies,
USA). To achieve optimal tissue miRNA profiles, we
carried out high-throughput next-generation sequencing
(Illumina, BGI, Shenzhen) of 12 NPC samples and 8
chronic nasopharyngitis samples by following the manu-
facturer’s recommended protocols. We screened the high
quality clean read sequences by the alignment to NCBI
GenBank data and miRBase 21.0 for the further analysis.
The raw data have been submitted to NCBI under BioPro-
ject accession No.PRJNA 289899.
Differential miRNA expression analysis
To identify miRNAs differentially expressed between NPC
patients and controls, we applied transcripts per million
(TPM) to normalize the expression of miRNA in two
groups (NPC and controls). Then we calculated fold change
(FC) and P-value via T-test, and corrected P-value into false
discovery rate (FDR) using the Benjamin and Hochberg
method [20]. FDR ≤ 0.05 and | log2FC | ≥ 2 were set as the
cut-offs to screen out differentially expressed miRNAs.
Quantitative reverse transcription–PCR analysis of miRNA
expression levels
Quantitative reverse transcription-PCR was used to val-
idate the sequencing results. Total RNA from 201 NPC
and 25 chronic nasopharyngitis biopsy specimens was
extracted using Trizol Reagent (Invitrogen, CA). Reverse
transcription of the total RNA was performed using All-
in-One First-Strand cDNA Synthesis kit (GeneCopoeia
Inc., USA) according to the manufacturer’s protocol.
Real-time PCR was performed by using All-in-OneTM
qPCR Mix (Applied GeneCopoeia Inc., USA) on Roche
Lightcycler 480 System. U6 snRNA was used as miRNA
endogenous control respectively. All samples were
normalized to internal control and fold changes were
calculated through relative quantification [21].
Bioinformatics analysis
Four softwares (RNAhybrid, TargetScan, Miranda, PITA)
were used for target gene prediction and only the genes
identified by all four approaches were selected out [22–25].
And we chose the overlapped genes targeted by oncogenic
miRNAs for further study, as well as the tumor suppressor
miRNAs. To understand the functions of predicted target
genes, Gene ontology (GO) and Kyoto encyclopedia of
genes and genomes (KEGG) enrichment analysis were per-
formed with package GO stats (http://www.geneontolo-
gy.org/) of P value <0.05 was set as the cut-off to select out
significantly enriched terms [26]. Then the miRNA
regulatory network analysis was performed using the IPA
software (http://www.ingenuity.com). The created genetic
networks describe functional relationships among miR-
NAs and genes based on known associations in the data-
bases [27]. Networks related were ranked according to
their biological relevance to the gene list provided.
Oligonucleotide transfection
Human nasopharyngeal carcinoma cell line CNE-2 was
cultured in RPMI-1640 (HyClone, Thermo scientific Inc,
China) supplemented with 10 % fetal bovine serum
(FBS, Gibco, Grand Island, NY, USA). CNE-2 was trans-
fected with miR-34c mimic or miR-Ctrl (20 nM; Ribobio,
Guangzhou, China) using lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA, USA). The cells were harvested
for assays 48 h after transfection.
Western blot
Proteins lysates extracted from cells were separated by 6
and 10 % SDS-PAGE, and electrophoretically transferred
to PVDF (polyvinylidene difluoride) membrane (Millipore).
Then the membranes were incubated with the following
antibodies: Met, Bcl-2, CDK6 (1:1000; Cell Signaling Tech-
nology, Beverly, MA, USA) and CCND1(1:500; ABclonal,
College Park, MD, USA), and followed by HRP (horse-
radish peroxidase)-labeled goat anti-rabbit IgG (1:5000;
Liankebio, Hanzhou, China) as secondary antibody. The
blots were visualized using the electrochemiluminescence
detection system. β-actin (1:1000; Cell Signaling Technol-
ogy, Beverly, MA, USA) was used as a protein loading
control.
Statistical analysis
Statistical analyses were conducted using spss19.0 soft-
ware. The data are shown as the mean ± SEM unless
otherwise noted. Two-tailed Student’s t test was used for
identify differentially expressed miRNAs between NPC
and controls. One-way ANOVA was used to show sig-
nificant associations between the miR-34c-5p level and
clinicopathological parameters. P values of <0.05 were
considered statistically significant.
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Results
Differentially expressed miRNAs between NPC and
controls
In order to isolate tumor cells from non-tumor cells, LCM
was performed on NPC and chronic nasopharyngitis
specimens (Fig. 1a). After normalization and T-test on
the sequencing data, 8 differentially expressed miRNAs
were screened, 4 up-regulated (miR-205-5p, miR-92a-3p,
miR-193b-3p and miR-27a-5p) and 4 down-regulated
(miR-34c-5p, miR-375, miR-92b-3p and miR-449c-5p)
(Table 2). Cluster analysis demonstrated that these
miRNAs could well distinguish the NPC samples from
controls (Fig. 1b). But the novel miRNAs mostly had
individual specificity, were not suitable for further
analysis.
Validation of expression of miRNAs
To confirm the deep sequencing results, we used qRT-PCR
to assess the expression of 8 miRNAs with an independent
cohort (including 65 NPC patients and 20 chronic naso-
pharyngitis patients). The relative level of each miRNA was
shown in Fig. 2a. Expression of 7 miRNAs measured by
qRT-PCR was dramatically different between NPC and
chronic nasopharyngitis tissues and significantly correlated
with their sequencing data. Because miR-92b-3p was not
reliably measured by qRT-PCR in the tissue specimens, it
was excluded from further analysis. The dynamic expres-
sion levels of miRNAs were revealed that the patterns were
classified into 2 groups, and the varying tendencies between
control and NPC were consistent with the sequencing
result (Fig. 2b, c). Moreover, the expression level of miR-
34c decreased with the ascent of clinical stage, which
implicated that miR-34c might be more important in
NPC progression.
Prediction and function analysis of target genes of
miRNAs
Functional analysis was conducted on genes predicted as
targets of 7 differentially expressed miRNAs by taking the
overlay part of 4 software results (RNAhybrid, TargetScan,
Miranda, PITA). 666 genes targeted by downregulated miR-
NAs and 248 genes targeted by upregulated miRNAs were
acquired after screening (Additional file 1: Table S1, S2).
The selected genes were analyzed by the Gene ontology
(GO) enrichment and Kyoto encyclopedia of genes and
genomes (KEGG) pathway analysis.
Fig. 1 MiRNA differential expression. a Laser capture microdessection of H&E-stained slides (×10). b Heatmap of normalized miRNA reads that are
differentially expressed between NPC and controls (sequencing-read count ratio ≥ 2.0, P < 0.05). Samples are well divided into control and NPC
patient groups
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The enrichment analysis of GO categories included
biological process (BP), molecular function (MF), and
cellular component (CC) three parts. The highest en-
richment were the terms like “Interleukin-1 secretion”,
“Mast cell activation involved in immune response”,
“Fibroblast growth factor binding”, “Lipopolysaccharide
binding” and “Cortical actin cytoskeleton” (Table 3).
These results showed the function of target genes mostly
focused on cell growth, secretion, migration and im-
mune system process.
The result of KEGG pathway analysis was enumerated
in Table 4. Chemokine signaling pathway, Cytokine-
cytokine receptor interaction and Cell cycle, Natural killer
cell mediated cytotoxicity, etc. were remarkable pathways
which could further confirm the target genes’ function in
tumor cell proliferation, secretion and tumor immunology.
So the differentially expressed miRNAs might be involved
in the development of NPC by targeting these genes.
Regulatory networks for differentially expressed miRNAs
The biological function analysis of target genes from
Ingenuity pathway analysis (IPA) database showed that
cancer was the top functional category which was sig-
nificantly related to the ectopic miRNAs, along with
embryonic and organismal development, which also could
be associated with cancer (Table 5). The filtering used in
IPA allowed us to connect 6 miRNAs with target genes.
In the regulation network of miRNA, miR-34 family
Table 2 Top 8 differentially expressed miRNAs
miRNA Average TPM in Control Average TPM in NPC Log2(FC) FDR
hsa-miR-27a-5p 0.03 79.7867 353.84 0.017
hsa-miR-193b-3p 1.403 73.4603 257.719 0.03
hsa-miR-92a-3p 4795.317 24268.259 4.5575 7.14E-3
hsa-miR-205-5p 3398.737 13008.145 3.9103 7.68E-4
hsa-miR-92b-3p 240483.065 25576.241 −10.7984 3.36E-4
hsa-miR-375 25725.996 405.155 - 226.8843 8.76E-3
hsa-miR-34c-5p 8338.523 79.437 - 565.0915 8.25E-3
hsa-miR-449c-5p 7473.709 24.586 −1968.9108 5.82E-4
Abbreviations: TPM transcripts per million, Control chronic nasopharyngitis sample, NPC nasopharyngeal carcinoma, FC fold change
Fig. 2 Validation of deregulated miRNAs by qRT-PCR. a An independent validation cohort included 65 NPC patients and 20 healthy control
subjects. b Dynamic expression of supregulated miRNA. c Dynamic expressions of downregulated miRNA. MicroRNA abundance was normalised
to U6 RNA. Statistical analysis was performed using the t-tests. *P < 0.01
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(including miR-34c-5p, miR-449c-5p) targeted the most
genes, and 5 directions of miR-34c come from experimen-
tal observations were highlighted (Fig. 3a). That indicated
the relationships between miR-34c and the 5 genes (TP53,
CCND1, BCL2, CDK6, MET) in cancer have already been
confirmed. The binding sites of miR-34c on these 5 genes
could be found through TargetScan software (Additional
file 2: Figure S1). CCND1, TP53 and BCL2 were clearly in
the center of network, so their related networks were
picked out for pathway construction. TP53 has been largely
confirmed as a tumor suppressor gene that mediated cell
cycle regulation with its downstream factors and could be
treated as diagnostic marker of NPC (Fig. 3b). And CCND1
and TP53 were both involved in PI3K/AKT/mTOR signal-
ing that modulated tumor cells growth and proliferation
(Fig. 3b, c). Sometimes they even induced apoptosis or
autophagy. Base on the IPA data, BCL2 could also be
predicted to be the diagnostic marker of NPC as TP53,
while it acted significantly in molecular mechanisms of can-
cer and functioned through apoptosis signaling (Fig. 3d).
Table 3 GO enrichment analysis of the target genes
ID Term Enrichment FDR
Cellular component GO:0030133 Transport vesicle 9.10473 2.50E-07
GO:0019898 Extrinsic to membrane 7.53782 0.0001
GO:0030864 Cortical actin cytoskeleton 21.17768 0.00036
GO:0048770 Pigment granule 5.527732 0.00066
Biological process GO:0048278 Vesicle docking 21.30266 1.95E-08
GO:0051047 Positive regulation of secretion 15.36585 6.06E-07
GO:0050701 Interleukin-1 secretion 66.95122 1.86E-06
GO:0002767 Immune response-inhibiting cell surface receptor signaling pathway 29.28 5.40E-06
GO:0002279 Mast cell activation involved in immune response 52.07317 1.09E-05
GO:0032512 Regulation of protein phosphatase type 2B activity 27.328 0.00456
GO:0032957 Inositol trisphosphate metabolic process 28.84053 0.0057
Molecular function GO:0035091 Phosphatidylinositol binding 11.07261 5.92E-09
GO:0008289 Lipid binding 3.68819 1.03E-06
GO:0034185 Apolipoprotein binding 18.24711 8.53E-06
GO:0017134 Fibroblast growth factor binding 39.21549 1.60E-05
GO:0004520 Endodeoxyribonuclease activity 13.72542 0.00011
GO:0001530 Lipopolysaccharide binding 34.22443 0.00063
GO:0015377 Cation:chloride symporter activity 10.70131 0.00387
GO:0016802 Trialkylsulfonium hydrolase activity 19.36428 0.00752
GO:0015140 Malate transmembrane transporter activity 33.88748 0.00785
GO:0032396 Inhibitory MHC class I receptor activity 33.88748 0.00785
Table 4 The KEGG pathway analysis of the target genes
Term ID Count Percentage P-value
Up-regulated miRNAs target gene KEGG-PATHWAY
Inositol phosphate metabolism ko00562 11 4.51 3.94E-6
Phopphatidylinositol signaling system ko04070 11 4.51 1.84E-4
Chemokine signaling pathway ko04062 12 4.92 4.58E-3
Down-regulated miRNAs target gene KEGG-PATHWAY
Natural killer cell mediated cytotoxicity ko04650 34 4.96 4.37E-9
Antigen processing and presentation ko04612 21 3.07 1.46E-8
Galactose metabolism ko00052 10 1.46 7.58E-5
Cell cycle ko04110 17 2.48 5.07E-3
Cytokine-cytokine receptor interaction ko04060 22 3.21 0.01523
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Comparison of miR-34c levels during NPC progression
As the previous results showed miR-34c might be more
valuable than others, miR-34c levels in more tissue samples
using qRT–PCR were further validated. A total of 201 NPC
tissue samples were used to validate miR-34c via qRT-PCR,
it was significantly reduced in NPC patients as compared
with controls (P < 0.01, Fig. 4a), and showed the signifi-
cant correlation with clinical stages respectively (P < 0.05,
Fig. 4b). All these data suggested that low concentration of
miR-34c was associated with higher tumour stage.
MiR-34c inhibited MET, CCND1, CDK6, BCL2 expression in
NPC cells
To further characterize whether these target genes (MET,
CCND1, CDK6, BCL2) respond to miR-34c in NPC cells,
CNE-2 cells were transfected with miR-34c mimic or miR-
Table 5 IPA analysis of target genes according to 7 dysregulated miRNAs
Top Networks(score) Top Diseases and Disorders
Cancer, Embryonic Development, Organismal Development (27) Cancer
Cardiovascular Disease, Developmental Disorder, Pulmonary Hypertension (27) Organismal Injury and Abnormalities
Cell Morphology, Cellular Assembly and Organization, Embryonic Development (27) Gastrointestinal Disease
Cancer, Organismal Injury and Abnormalities, Cellular Growth and Proliferation (27) Hepatic System Disease
Cancer, Dermatological Diseases and Conditions, Organismal Injury and Abnormalities (25) Reproductive System Disease
Fig. 3 MiRNAs regulatory networks by IPA. a The miRNA-mRNA interaction network. miR-34 family targeted most genes and the relationship
between it and 5 highlighted genes (CCND1, TP53, BCL2, MET, CDK6) was experimentally confirmed. b TP53-centered network showed TP53
could be treated as diagnostic marker of NPC and was involved in cell cycle regulation and mTOR signaling. c CCND1- centered network
indicated CCND1 was involved in both p53 signaling and PI3K/AKT/mTOR signaling. d BCL2-centered network showed BCL2 acted significantly in
molecular mechanisms of cancer and functioned through apotosis signaling
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Ctrl. Western blot was performed to detect the expression
level of MET, CCND1, CDK6 and BCL2. As shown in
Fig. 4c, the overexpression of miR-34c with miR-34c
mimics led to a notable decrease in these four genes
protein levels compared with the negative control in
CNE-2 cells. These results indicated that MET, CCND1,
CDK6 and BCL2 were actually targeted by miR-34c in
NPC cells.
Discussion
We analyzed the miRNA expression profile from 12
NPC and 8 chronic nasopharyngitis tissues after LCM
with the RNA-seq technology in this study. Deregulated
miRNAs were screened from the statistical analyses and
a panel of 7 significantly differentially expressed miRNAs
(miR-34c-5p, miR-375, miR-449c-5p, miR-205-5p, miR-
92a-3p, miR-193b-3p and miR-27a-5p) was found to be
an effective regulatory factor between NPC and controls.
And our result was also consistent with many studies of
other tumors, including miR-34c and miR-375, which
were both downregulated in colorectal carcinoma [28, 29],
and miR-449c was showed to inhibit gastric carcinoma
growth [30]. On the contrary, miR-205, miR-92a, miR-
193b and miR-27a-5p were reported to be upregulated
in other kinds of cancers, including lung cancer, cervical
cancer, glioma and renal cell carcinoma [31–34].
According to our expression profile of miRNA, there
is no study about the deregulated expression of miR-27a-
5p, miR-193-3p, miR-449c-5p or miR-92a-3p in NPC yet.
Mir-375 expression was significantly reduced in NPC and
inhibited tumor growth by targeting MTDH [35]. The
results of Tang et al. implicated miR-205-5p may be a
novel NPC candidate biomarker, which was showed to
determine the radioresistance of NPC through the miR-
205-PTEN-Akt pathway [36]. The reduced expression
of miR-34c frequently occurred in many studies of NPC,
which was believed to play important role in NPC. The re-
cent study of Li et al. proved that miR-34c suppressed
NPC cell viability, colony formation by targeting MET
[37]. Our study also showed the miR-34c level in NPC
tissues got a decreasing trend during NPC progression
via qRT-PCR.
Nevertheless, it has been known that miRNAs always
functioned not only through one single gene, but a huge
network which covered multiple genes. For a deeper
understanding of the functional genomic alterations
induced by deregulated miRNAs, target genes were
predicted by multiple softwares included RNAhybrid,
TargetScan, Miranda and PITA, and the bioinformatics
analysis of the functional category and integrated network
were conducted, including GO, KEGG enrichment ana-
lysis and IPA. The GO enrichment analysis found that
the target genes of these dysregulated miRNAs were associ-
ated with cell growth, protein binding and secretion, which
were all involved in tumorigenesis, KEGG analysis also ob-
tained similar results (Table 3, Table 4). Interestingly, the
“Natural killer cell mediated cytotoxicity” was the top term
in KEGG analysis and the genes involved in this process
were all targeted by miR-34c, which meant tumor immun-
ology should not be ignored in NPC pathogenesis. Recent
Fig. 4 MiR-34c levels during NPC progression and target genes validation. a The expression level of miR-34c-5p in human NPC specimens compared
with control biopsy samples. b miR-34c-5p expression was higher in stage I, whereas stages II-IV had lower levels. c The protein expression levels of
MET, CCND1, CDK6 and BCL2 in miR-34c mimic transfected CNE-2 cells were lower than the controls. Western blot was independently repeated at
least three times. MicroRNA abundance was normalised to U6 RNA. Statistical analysis was performed using the t-tests (a, c) and the one-way
ANOVA (b)
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studies showed miR-34c could affect NK cell’s activation in
melanoma [38], indicating an exciting future in the field of
NK cell-based cancer immunotherapy [39].
MiRNAs regulatory network from IPA data showed
the relationships between 5 target genes (TP53, CCND1,
BCL2, CDK6, MET) and miR-34c in various cancers
were experimental confirmed and located in the center
of network (Fig. 3a). TP53, CCND1 and BCL2 were
demonstrated to modulate tumor cells growth and pro-
liferation via PI3K/AKT/mTOR signaling. These results
indicated the downregulation of miR-34c might play an
important role in NPC.
TP53 is predicted to be a diagnostic marker of NPC in
IPA, which functions as a tumor suppressor protein that
can induce cell cycle arrest and apoptosis. It was deemed
to positively play a synergetic role in suppressing NPC
tumorigenesis with miR-34 family not like miR-125a/b or
miR-BHRF-1 which directly downregulated TP53 [40–42].
This further demonstrates that in the pathogenesis of
NPC, even a single gene can be regulated by many factors,
the exploration of miRNA regulatory network is especially
vital in miRNA integrated analysis of NPC.
CCND1, CDK6 and BCL2 are all cell cycle regulators.
CCND1 usually functions as a regulatory subunit of CDK6,
whose activity is required for cell cycle G1/S transition and
thought to be an oncogene in various tumors including
NPC. The expression level of CCND1 was related to radio-
sensitivity in NPC treatment [43]. Previous studies showed
EBV could encoded LMP1 to enhance the promoter activity
of CCND1 in NPC, and miR-144 suppressed the expression
of PTEN to increase the expression of CCND1 to promote
tumor migration and invasion [44, 45]. Our results indi-
cated that CCND1 might be a target gene of miR-34c in
NPC, which should be further confirmed in future. As one
target of CCND1, CDK6 is important for cell cycle G1
phase progression and G1/S transition, while miR-26a
can suppress CDK6 expression through EZH2 to in-
hibit tumorigenesis of NPC [46]. BCL2 acted as the
anti-apoptotic protein by increasing the rate of cell div-
ision and arresting cells in the G0/G1 checkpoint of the
cell cycle, and it could also be treated as a diagnosis
marker as TP53 [47]. Mir-21 could target BCL2 directly
to suppress NPC cells proliferation and migration, while
PDCD4 regulated its expression level via modulating
miR-184 [48, 49].
The mechanism of MET in many tumors has been
well explored in various research [50, 51]. In NPC, miR-
34c had been clearly proved to target MET [37], and it
was activated by hepatocyte growth factor (HGF), then
modulated cellular proliferation, migration, invasion via
inhibition of EGR-1 expression [52, 53]. Furthermore,
PHA-665752, MET inhibitor, could furthermore effectively
affect the radiosensitivity of NPC and suppress NPC cells
proliferation [54]. Hence, Li et al. showed MET protein
overexpression and gene amplification were independent
prognostic factors and might be treated as therapeutic bio-
markers in NPC [55].
Above all mentioned, the PI3K/AKT/mTOR signaling
was considered as the function pathway of deregulated
miRNAs to mediate cellular growth and proliferation,
apoptosis and autophagy. CCND1, CKD6, BCL2 and
TP53 worked together on cell circle regulation, while
MET was also significant in NPC cellular proliferation,
migration and invasion, and might work through other
pathways. MiR-34c was thought to be the key factor in
this network. And our qRT-PCR results further con-
firmed the expression level of miR-34c decreased with
the ascent of tumor stage (Fig. 4b). So we hypothesized
miR-34c regulated NPC development through the net-
work constructed by these factors and inferred their
mechanism in NPC respectively in this model (Fig. 5).
Conclusions
In conclusion, our study disclosed a global profiling of
differentially expressed miRNAs that was closely related
with NPC carcinogenesis and progression. For a better
understanding of the miRNA regulation on genome-wide
repression and activation, we use integrated approaches
including GO, KEGG and IPA. In the miRNA regulatory
network, miR-34c and its target genes including TP53,
CCND1, BCL2, CDK6 and MET are shown to play
Fig. 5 MiR-34c regulatory network. Blue fonts represent tumor
supressor factors while red fonts represent oncogenic factors. The
interaction between miRNAs and mRNAs demonstrate miR-34c-5p
might regulates NPC cellular growth and migration, apoptosis via these
genes and functions through PI3K/AKT/mTOR signaling. → Direct
Stimulatory Modification, →→Multistep Stimulatory Modification,
−Direct Inhibitory Modification, −Tentative Associated Modification
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important roles in NPC, and the PI3K/AKT/mTOR
signaling is regarded as a significant function pathway
mediated by miR-34c. Among these differentially expressed
miRNAs, miR-34c expression decreases during NPC devel-
opment, indicating it as a potential biomarker monitoring
NPC progression. Thus, miR-34c may be the key modula-
tor in the process of tumorigenesis and treated as the
biomarker of NPC in future research.
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